Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
07
11
2019
accepted:
14
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Ascaris lumbricoides is one of the three major soil-transmitted gastrointestinal helminths (STHs) that infect more than 440 million people in the world, ranking this neglected tropical disease among the most common afflictions of people living in poverty. Children infected with this roundworm suffer from malnutrition, growth stunting as well as cognitive and intellectual deficits. An effective vaccine is urgently needed to complement anthelmintic deworming as a better approach to control helminth infections. As37 is an immunodominant antigen of Ascaris suum, a pig roundworm closely related to the human A. lumbricoides parasite, recognized by protective immune sera from A. suum infected mice. In this study, the immunogenicity and vaccine efficacy of recombinant As37 were evaluated in a mouse model. As37 was cloned and expressed as a soluble recombinant protein (rAs37) in Escherichia coli. The expressed rAs37 was highly recognized by protective immune sera from A. suum egg-infected mice. Balb/c mice immunized with 25 μg rAs37 formulated with AddaVax™ adjuvant showed significant larval worm reduction after challenge with A. suum infective eggs when compared with a PBS (49.7%) or adjuvant control (48.7%). Protection was associated with mixed Th1/2-type immune responses characterized by high titers of serological IgG1 and IgG2a and stimulation of the production of cytokines IL-4, IL-5, IL-10 and IL-13. In this experiment, the AddaVax™ adjuvant induced better protection than the Th1-type adjuvant MPLA (38.9%) and the Th2-type adjuvant Alhydrogel (40.7%). Sequence analysis revealed that As37 is a member of the immunoglobulin superfamily (IgSF) and highly conserved in other human STHs. Anti-As37 antibodies strongly recognized homologs in hookworms (Necator americanus, Ancylostoma ceylanicum, A. caninum) and in the whipworm Trichuris muris, but there was no cross-reaction with human spleen tissue extracts. These results suggest that the nematode-conserved As37 could serve as a pan-helminth vaccine antigen to prevent all STH infections without cross-reaction with human IgSF molecules. As37 is an A. suum expressed immunodominant antigen that elicited significant protective immunity in mice when formulated with AddaVax™. As37 is highly conserved in other STHs, but not in humans, suggesting it could be further developed as a pan-helminth vaccine against STH co-infections.
Sections du résumé
BACKGROUND
Ascaris lumbricoides is one of the three major soil-transmitted gastrointestinal helminths (STHs) that infect more than 440 million people in the world, ranking this neglected tropical disease among the most common afflictions of people living in poverty. Children infected with this roundworm suffer from malnutrition, growth stunting as well as cognitive and intellectual deficits. An effective vaccine is urgently needed to complement anthelmintic deworming as a better approach to control helminth infections. As37 is an immunodominant antigen of Ascaris suum, a pig roundworm closely related to the human A. lumbricoides parasite, recognized by protective immune sera from A. suum infected mice. In this study, the immunogenicity and vaccine efficacy of recombinant As37 were evaluated in a mouse model.
METHODOLOGY/PRINCIPAL FINDINGS
As37 was cloned and expressed as a soluble recombinant protein (rAs37) in Escherichia coli. The expressed rAs37 was highly recognized by protective immune sera from A. suum egg-infected mice. Balb/c mice immunized with 25 μg rAs37 formulated with AddaVax™ adjuvant showed significant larval worm reduction after challenge with A. suum infective eggs when compared with a PBS (49.7%) or adjuvant control (48.7%). Protection was associated with mixed Th1/2-type immune responses characterized by high titers of serological IgG1 and IgG2a and stimulation of the production of cytokines IL-4, IL-5, IL-10 and IL-13. In this experiment, the AddaVax™ adjuvant induced better protection than the Th1-type adjuvant MPLA (38.9%) and the Th2-type adjuvant Alhydrogel (40.7%). Sequence analysis revealed that As37 is a member of the immunoglobulin superfamily (IgSF) and highly conserved in other human STHs. Anti-As37 antibodies strongly recognized homologs in hookworms (Necator americanus, Ancylostoma ceylanicum, A. caninum) and in the whipworm Trichuris muris, but there was no cross-reaction with human spleen tissue extracts. These results suggest that the nematode-conserved As37 could serve as a pan-helminth vaccine antigen to prevent all STH infections without cross-reaction with human IgSF molecules.
CONCLUSIONS/SIGNIFICANCE
As37 is an A. suum expressed immunodominant antigen that elicited significant protective immunity in mice when formulated with AddaVax™. As37 is highly conserved in other STHs, but not in humans, suggesting it could be further developed as a pan-helminth vaccine against STH co-infections.
Identifiants
pubmed: 32053593
doi: 10.1371/journal.pntd.0008057
pii: PNTD-D-19-01914
pmc: PMC7017989
doi:
Substances chimiques
Antibodies, Helminth
0
Antigens, Helminth
0
Helminth Proteins
0
Soil
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008057Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
Development. 2003 Dec;130(25):6317-28
pubmed: 14623821
Vaccine. 2012 May 14;30(23):3478-82
pubmed: 22465737
J Immunol Methods. 2017 Jan;440:74-82
pubmed: 27840065
PLoS One. 2013 Oct 10;8(10):e77238
pubmed: 24130862
Drugs. 2000 Nov;60(5):985-95
pubmed: 11129130
Vaccine. 2013 Apr 18;31 Suppl 2:B227-32
pubmed: 23598487
Exp Parasitol. 2008 Jan;118(1):32-40
pubmed: 17645877
J Clin Invest. 2008 Apr;118(4):1311-21
pubmed: 18382743
Immunol Rev. 1998 Jun;163:197-215
pubmed: 9700512
PLoS Negl Trop Dis. 2017 Jul 14;11(7):e0005769
pubmed: 28708895
Exp Parasitol. 1985 Oct;60(2):245-54
pubmed: 4029352
J Mol Biol. 1994 May 13;238(4):528-39
pubmed: 8176743
Parasit Vectors. 2016 Sep 27;9(1):518
pubmed: 27677574
Hum Vaccin Immunother. 2013 Nov;9(11):2351-61
pubmed: 23880663
J Mol Biol. 2000 Mar 10;296(5):1367-83
pubmed: 10698639
J Mol Biol. 2016 Feb 22;428(4):702-708
pubmed: 26517951
Hum Vaccin Immunother. 2012 Apr;8(4):486-90
pubmed: 22832252
Int J Cell Biol. 2012;2012:340296
pubmed: 22272201
Vaccine. 2013 Jul 18;31(33):3363-9
pubmed: 23684834
Microbiol Spectr. 2016 Oct;4(5):
pubmed: 27780017
J Infect Dis. 2004 Nov 15;190(10):1812-20
pubmed: 15499538
Int J Parasitol. 2002 Dec 19;32(14):1739-46
pubmed: 12464420
Electrophoresis. 1997 Dec;18(15):2714-23
pubmed: 9504803
Arch Dis Child. 2013 Aug;98(8):635-41
pubmed: 23793132
Am J Trop Med Hyg. 2013 Jul;89(1):23-31
pubmed: 23690551
Int J Parasitol. 2005 Aug;35(9):1023-30
pubmed: 15998515
Immunology. 1977 Apr;32(4):405-11
pubmed: 608676
Curr Opin Infect Dis. 2012 Dec;25(6):709-17
pubmed: 23041774
FASEB J. 2005 Oct;19(12):1743-5
pubmed: 16037096
PLoS Med. 2012 Jan;9(1):e1001162
pubmed: 22291577
PLoS Negl Trop Dis. 2015 Apr 30;9(4):e0003618
pubmed: 25928617
Eur J Immunol. 1992 Jul;22(7):1919-25
pubmed: 1623930
Front Immunol. 2018 Nov 09;9:2535
pubmed: 30473693
PLoS Negl Trop Dis. 2016 Jan 27;10(1):e0004382
pubmed: 26814713
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W465-9
pubmed: 18424797
Int J Parasitol. 1990 Feb;20(1):77-81
pubmed: 2312230
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Infect Immun. 2003 Dec;71(12):6915-20
pubmed: 14638780
Infect Immun. 2006 Jun;74(6):3232-8
pubmed: 16714550
Am J Vet Res. 1984 Oct;45(10):2104-8
pubmed: 6497109
Neuron. 1996 Feb;16(2):261-73
pubmed: 8789942
Int J Parasitol Drugs Drug Resist. 2011 Oct 14;1(1):14-27
pubmed: 24533260
Mol Biochem Parasitol. 2003 Jan;126(1):63-71
pubmed: 12554085
J Exp Med. 1999 Oct 4;190(7):953-62
pubmed: 10510085
Parasite Immunol. 2007 Nov;29(11):583-94
pubmed: 17944748
Pharm Biotechnol. 1995;6:277-96
pubmed: 7551221
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2562
pubmed: 24340111
Infect Immun. 2003 Sep;71(9):5314-23
pubmed: 12933879
Trends Parasitol. 2016 Oct;32(10):798-807
pubmed: 27262918
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Cell Mol Life Sci. 2008 Oct;65(20):3231-40
pubmed: 18668203
PLoS Negl Trop Dis. 2009;3(3):e400
pubmed: 19333373
Infect Immun. 2001 Dec;69(12):7285-92
pubmed: 11705899
Int J Parasitol. 2013 Aug;43(9):697-706
pubmed: 23665127
Nucleic Acids Res. 2003 Jul 1;31(13):3320-3
pubmed: 12824317
Annu Rev Immunol. 1988;6:381-405
pubmed: 3289571
Annu Rev Cell Dev Biol. 1997;13:425-56
pubmed: 9442880
Nat Genet. 2014 Jul;46(7):693-700
pubmed: 24929830
Expert Rev Vaccines. 2014 Mar;13(3):321-31
pubmed: 24392641